Carbohydrate-Based Antibacterial Vaccines

Carbohydrate-Based Vaccines and Immunotherapies

Volumn , Issue , 2008, Pages 117-166

  Pon, Robert A ^a   Jennings, Harold J ^a  

^a NATIONAL RESEARCH COUNCIL CANADA   (Canada)

Author keywords

Carbohydrate based antibacterial vaccines; First generation conjugate vaccines in humans and new and improved vaccines; PnC7 CRM and invasive pneumococcal disease (IPD) in infants

Indexed keywords

EID: 84889318545     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470473283.ch4     Document Type: Chapter

References (281)

1. Schiemann O, Casper W (1927) Sind die spezifisch pracipitablen Substanzen der 3 Pneumokokkentypen Haptene? Med. Microbiol. Immunol. 108:220-257.
2. Tillett WS, Francis T, Jr (1929) Cutaneous reactions to the polysaccharides and proteins of pneumococcus in lobar pneumonia. J. Exp. Med. 50:687-701.
3. MacLeod CM, Hodges RG, Heidelberger M, Bernhard WG (1945) Prevention of pneumococcal pneumonia by immunization with specific capsular polysaccharides. J. Exp. Med. 82:445-465.
4. Kelly DF, Moxon ER, Pollard AJ (2004) Haemophilus influenzae type b conjugate vaccines. Immunology 113:163-174.
5. Avery OT, Goebel WF (1929) Chemo-immunological studies on conjugated carbohydrate-proteins: II. Immunological specificity of synthetic sugar-protein antigens. J. Exp. Med. 50:533-550.
6. Jennings HJ, Sood RK (1994) Synthetic glycoconjugates as human vaccines. In Lee YC, Lee RT, Eds. Neoglycoconjugates. Preparation and Applications. Academic, London, pp. 325-371.
7. Jennings HJ, Pon RA (1996) Polysaccharides and glycoconjugates as human vaccines. In Dimitriu S, Ed. Polysaccharides in Medicinal Applications. Marcel Dekker, New York, pp. 473-479.
8. Robbins JB, Schneerson R, Szu SC, Pozsgay V (1999) Bacterial polysaccharide-protein conjugate vaccines. Pure Appl. Chem. 71:745-754.
9. Jennings HJ (1998) Polysaccharide vaccines against disease caused by Haemophilus influenzae, group B Streptococcus, and Salmonella typhi. Carbohydrates Eur. 21:17-23.
10. Stein KE (1992) Thymus-independent and thymus-dependent responses to polysaccharide antigens. J. Infect. Dis. 165(Suppl 1S49-S52.
11. Dintzis RZ, Okajima M, Middleton MH, Greene G, DintzisHM (1989) The immunogenicity of soluble haptenated polymers is determined by molecular mass and hapten valence. J. Immunol. 143:1239-1244.
12. Scott MG, Zachau HG, Nahm MH (1992) The human antibody V region repertoire to the type B capsular polysaccharide of Haemophilus influenzae. Int. Rev. Immunol. 9:45-55.
13. Jeurissen A, Wuyts G, Kasran A, Ramdien-Murli S, Blanckaert N, Boon L, Ceuppens JL, Bossuyt X (2004) The human antibody response to pneumococcal capsular polysaccharides is dependent on the CD40-CD40 ligand interaction. Eur. J. Immunol. 34:850-858.
14. Jeurissen A, Billiau AD, Moens L, Shengqiao L, LanduytW, Wuyts G, Boon L,Waer M, Ceuppens JL, Bossuyt X (2006) CD4+ T lymphocytes expressing CD40 ligand help the IgM antibody response to soluble pneumococcal polysaccharides via an intermediate cell type. J. Immunol. 176:529-536.
15. Sen G, Khan AQ, Chen Q, Snapper CM (2005) In vivo humoral immune responses to isolated pneumococcal polysaccharides are dependent on the presence of associated TLR ligands. J. Immunol. 175:3084-3091.
16. Snapper CM, Mond JJ (1996) A model for induction of T cell-independent humoral immunity in response to polysaccharide antigens. J. Immunol. 157:2229-2233.
17. Heidelberger M, Dilapi MM, Siegel M, Walter AW (1950) Persistence of antibodies in human subjects injected with pneumococcal polysaccharides. J.Immunol. 65:535-541.
18. McHeyzer-Williams LJ, McHeyzer-WilliamsMG (2005) Antigen-specific memory B cell development. Annu. Rev. Immunol. 23:487-513.
19. Crotty S, Ahmed R (2004) Immunological memory in humans. Semin. Immunol. 16:197-203.
20. Insel RA, Anderson PW (1986) Oligosaccharide-protein conjugate vaccines induce and prime for oligoclonal IgG antibody responses to the Haemophilus influenzae b capsular polysaccharide in human infants. J. Exp. Med. 163:262-269.
21. Insel RA, Adderson EE, Carroll WL (1992) The repertoire of human antibody to the Haemophilus influenzae type b capsular polysaccharide. Int. Rev. Immunol. 9:25-43.
22. Hougs L, Juul L, Ditzel HJ, Heilmann C, Svejgaard A, Barington T (1999) The first dose of a Haemophilus influenzae type b conjugate vaccine reactivates memory B cells: Evidence for extensive clonal selection, intraclonal affinity maturation, and multiple isotype switches to IgA2. J. Immunol. 162:224-237.
23. Jakobsen H, Hannesdottir S, Bjarnarson SP, Schulz D, Trannoy E, Siegrist CA, Jonsdottir I (2006) Early life T cell responses to pneumococcal conjugates increase with age and determine the polysaccharide-specific antibody response and protective efficacy. Eur. J. Immunol. 36:287-295.
24. Clutterbuck EA, Salt P, Oh S, Marchant A, Beverley P, Pollard AJ (2006) The kinetics and phenotype of the human B-cell response following immunization with a heptavalent pneumococcal-CRM conjugate vaccine. Immunology 119:328-337.
25. Goldblatt D, Richmond P, Millard E, Thornton C, Miller E (1999) The induction of immunologic memory after vaccination with Haemophilus influenzae type b conjugate and acellular pertussis-containing diphtheria, tetanus, and pertussis vaccine combination. J. Infect. Dis. 180:538-541.
26. Guirola M, Urquiza D, Alvarez A, Cannan-Haden L, Caballero E, Guillen G (2006) Immunologic memory response induced by a meningococcal serogroup C conjugate vaccine using the P64k recombinant protein as carrier. FEMS Immunol. Med. Microbiol. 46:169-179.
27. Anon (1989) Pneumococcal polysaccharide vaccine. MMWR Morb. Mortal. Wkly. Rep. 38:64-66.
28. Lee CJ (1996) Bacterial capsular polysaccharides. In Dimitriu S, Ed. Polysaccharides in Medicinal Applications. Marcel Dekker, New York, pp. 411-441.
29. Trollfors B, Lagergard T, Claesson BA, Thornberg E, Martinell J, Schneerson R (1992) Characterization of the serum antibody response to the capsular polysaccharide of Haemophilus influenzae type b in children with invasive infections. J. Infect. Dis. 166:1335-1339.
30. Schneerson R, Robbins JB (1975) Induction of serum Haemophilus influenzae type B capsular antibodies in adult volunteers fed cross-reacting Escherichia coli 075 : K100 : H5. N. Engl. J. Med. 292:1093-1096.
31. Guinamard R, Okigaki M, Schlessinger J, Ravetch JV (2000) Absence of marginal zone B cells in Pyk-2-deficient mice defines their role in the humoral response. Nat. Immunol. 1:31-36.
32. Jeurissen A, Ceuppens JL, Bossuyt X (2004) T lymphocyte dependence of the antibody response to T lymphocyte independent type 20 antigens. Immunology 111:1-7.
33. Weller S, Faili A, Aoufouchi S, Gueranger Q, Braun M, Reynaud CA, Weill JC (2003) Hypermutation in human B cells in vivo and in vitro. Ann. N.Y. Acad. Sci. 987:158-165.
34. Gold R, Lepow ML, Goldschneider I, Draper TF, Gotshlich EC (1979) Kinetics of antibody production to group A and group C meningococcal polysaccharide vaccines administered during the first six years of life: Prospects for routine immunization of infants and children. J. Infect. Dis. 140:690-697.
35. Makela PH, Sibakov M, Herva E, Henrichsen J, Luotonen J, Timonen M, Leinonen M, Koskela M, Pukander J, Pontynen S, Gronroos P, Karma P (1980) Pneumococcal vaccine and otitis media. Lancet 2:547-551.
36. Makela PH, Peltola H, Kayhty H, Jousimies K, Pettay O (1977) Polysaccharide vaccines of group A Neisseria meningitidis and Haemophilus influenzae type b: A field trial in Finland. J. Infect. Dis. 136(Suppl):43-50.
37. Wessels MR, Kasper DL, Johnson KD, Harrison LH (1998) Antibody responses in invasive group B streptococcal infection in adults. J. Infect. Dis. 178:569-572.
38. Butcher S, Chahel H, Lord JM (2000) Reviewarticle: Ageing and the neutrophil: No appetite for killing? Immunology 100:411-416.
39. Hedlund J, Ortqvist A, Konradsen HB, Kalin M (2000) Recurrence of pneumonia in relation to the antibody response after pneumococcal vaccination in middle-aged and elderly adults. Scand. J. Infect. Dis. 32:281-286.
40. Overturf GD (2002) Pneumococcal vaccination of children. Semin. Pediatr. Infect. Dis. 13:155-164.
41. Singleton RJ, Butler JC, Bulkow LR, Hurlburt D, O'Brien KL, Doan W, Parkinson AJ, Hennessy TW (2007) Invasive pneumococcal disease epidemiology and effectiveness of 23-valent pneumococcal polysaccharide vaccine in Alaska native adults. Vaccine 25:2288-2295.
42. Bar-Zeev N, Buttery JP (2006) Combination conjugate vaccines. Expert. Opin. Drug Saf. 5:351-360.
43. Anon (1991) Haemophilus b conjugate vaccines for prevention of Haemophilus influenzae type b disease among infants and children two months of age and older. Recommendations of the immunization practices advisory committee (ACIP). MMWR Recomm. Rep. 40:1-7.
44. Anderson P, Peter G, Johnston R-BJ, Wetterlow LH, Smith DH (1972) Immunization of humans with polyribophosphate, the capsular antigen of Hemophilus influenzae, type b. J. Clin. Invest. 51:39-44.
45. Parke J-CJ, Schneerson R, Robbins JB, Schlesselman JJ (1977) Interim report of a controlled field trial of immunization with capsular polysaccharides of Haemophilus influenzae type b and group C Neisseria meningitidis in Mecklenburg county, North Carolina (March 1974-March 1976). J. Infect. Dis. 136(SupplS51-S56.
46. Smith DH, Peter G, Ingram DL, Harding AL, Anderson P (1973) Responses of children immunized with the capsular polysaccharide of Hemophilus influenzae, type b. Pediatrics 52:637-644.
47. Kayhty H, Karanko V, Peltola H, Makela PH (1984) Serum antibodies after vaccination with Haemophilus influenzae type b capsular polysaccharide and responses to reimmunization: No evidence of immunologic tolerance or memory. Pediatrics 74:857-865.
48. Schneerson R, Barrera O, Sutton A, Robbins JB (1980) Preparation, characterization, and immunogenicity of Haemophilus influenzae type b polysaccharide-protein conjugates. J. Exp. Med. 152:361-376.
49. Verez-Bencomo V, Fernandez-Santana V, Hardy E, Toledo ME, Rodriguez MC, Heynngnezz L, Rodriguez A, Baly A, Herrera L, Izquierdo M, Villar A, Valdes Y, Cosme K, Deler ML, Montane M, Garcia E, Ramos A, Aguilar A, Medina E, Torano G, Sosa I, Hernandez I, Martinez R, Muzachio A, Carmenates A, Costa L, Cardoso F, Campa C, Diaz M, Roy R (2004) A synthetic conjugate polysaccharide vaccine against Haemophilus influenzae type b. Science 305:522-525.
50. Anon (2006) Recommended childhood and adolescent immunization schedule-United States, 2006. MMWR Morb. Mortal. Wkly. Rep. 54:Q1-Q4.
51. Claesson BA, Trollfors B, Lagergard T, Knutsson N, Schneerson R, Robbins JB (2005) Antibodies against Haemophilus influenzae type b capsular polysaccharide and tetanus toxoid before and after a booster dose of the carrier protein nine years after primary vaccination with a protein conjugate vaccine. Pediatr. Infect. Dis. J. 24:463-464.
52. Eskola J, Ward J, Dagan R, Goldblatt D, Zepp F, Siegrist CA (1999) Combined vaccination of Haemophilus influenzae type b conjugate and diphtheria-tetanus-pertussis containing acellular pertussis. Lancet 354:2063-2068.
53. Mulholland K, Hilton S, Adegbola R, Usen S, Oparaugo A, Omosigho C, Weber M, Palmer A, Schneider G, Jobe K, Lahai G, Jaffar S, Secka O, Lin K, Ethevenaux C, Greenwood B (1997) Randomised trial of Haemophilus influenzae type-b tetanus protein conjugate vaccine [corrected] for prevention of pneumonia and meningitis in Gambian infants. Lancet 349:1191-1197.
54. Booy R, Hodgson S, Carpenter L, Mayon-White RT, Slack MP, Macfarlane JA, Haworth EA, Kiddle M, Shribman S, Roberts JS, Moxon ER (1994) Efficacy of Haemophilus influenzae type b conjugate vaccine PRP.-T. Lancet 344:362-366.
55. Vadheim CM, Greenberg DP, Partridge S, Jing J, Ward JI (1993) Effectiveness and safety of an Haemophilus influenzae type b conjugate vaccine (PRP-T) in young infants. Kaiser-UCLA Vaccine Study Group. Pediatrics 92:272-279.
56. Obonyo CO, Lau J (2006) Efficacy of Haemophilus influenzae type b vaccination of children: A meta-analysis. Eur. J. Clin. Microbiol. Infect. Dis. 25:90-97.
57. Black SB, Shinefield HR, Fireman B, Hiatt R, Polen M, Vittinghoff E (1991) Efficacy in infancy of oligosaccharide conjugate Haemophilus influenzae type b (HbOC) vaccine in a United States population of 61,080 children. The Northern California Kaiser Permanente Vaccine Study Center Pediatrics Group. Pediatr. Infect. Dis. J. 10:97-104.
58. Ward J, Brenneman G, Letson GW, Heyward WL (1990) Limited efficacy of a Haemophilus influenzae type b conjugate vaccine in Alaska Native infants. The Alaska H. influenzae Vaccine Study Group. N. Engl. J. Med. 323:1393-1401.
59. Chandran A,Watt JP, Santosham M (2005) Prevention of Haemophilus influenzae type b disease: Past success and future challenges. Expert. Rev. Vaccines 4:819-827.
60. Granoff DM, Holmes SJ, Osterholm MT, McHugh JE, Lucas AH, Anderson EL, Belshe RB, Jacobs JL, Medley F, Murphy TV (1993) Induction of immunologic memory in infants primed with Haemophilus influenzae type b conjugate vaccines. J. Infect. Dis. 168:663-671.
61. Anon (2002) Progress toward elimination of Haemophilus influenzae type b invasive disease among infants and children-United States, 1998-2000. MMWR Morb. Mortal. Wkly. Rep. 51:234-237.
62. Barbour ML, Mayon-White RT, Coles C, Crook DW, Moxon ER (1995) The impact of conjugate vaccine on carriage of Haemophilus influenzae type b. J. Infect. Dis. 171:93-98.
63. Takala AK, Eskola J, Leinonen M, Kayhty H, Nissinen A, Pekkanen E, Makela PH (1991) Reduction of oropharyngeal carriage of Haemophilus influenzae type b (Hib) in children immunized with an Hib conjugate vaccine. J. Infect. Dis. 164:982-986.
64. Rosenstein NE, Perkins BA, Stephens DS, Lefkowitz L, Cartter ML, Danila R, Cieslak P, Shutt KA, Popovic T, Schuchat A, Harrison LH, Reingold AL (1999) The changing epidemiology of meningococcal disease in the United States, 1992-1996. J. Infect. Dis. 180:1894-1901.
65. Anon (2003) Summary of notifiable diseases-United States, 2001. MMWR Morb. Mortal. Wkly. Rep. 50:i-108.
66. Rosenstein NE, Perkins BA, Stephens DS, Popovic T, Hughes JM (2001) Meningococcal disease. N. Engl. J. Med. 344:1378-1388.
67. Goldschneider I, Gotschlich EC, Artenstein MS (1969) Human immunity to the meningococcus. I. The role of humoral antibodies. J. Exp. Med. 129:1307-1326.
68. Wahdan MH, Rizk F, El Akkad AM, El Ghoroury A, Hablas R, Girgis NI, Amer A, Boctar W, Sippel JE, Gotschlich EC, Triau R, Sanborn WR, Cvjetanovic B (1973) A controlled field of a serogroup A meningococcal polysaccharide vaccine. Bull. World Health Organ. 48:667-673.
69. Soriano-Gabarro M, Toe L, Tiendrebeogo SR, Nelson CB, Dabal M, Djingarey MH, Plikaytis B, Rosenstein N (2007) Effectiveness of a trivalent serogroup A/C/W135 meningococcal polysaccharide vaccine in Burkina Faso, 2003. Vaccine 25(Suppl 1): A92-A96.
70. Anon (1985) Recommendation of the Immunization Practices Advisory Committee Meningococcal Vaccines. MMWR Morb. Mortal. Wkly. Rep. 34:255-259.
71. Soriano-Gabarro M, Toe L, Tiendrebeogo SR, Nelson CB, Dabal M, Djingarey MH, Plikaytis B, Rosenstein N (2007) Effectiveness of a trivalent serogroup A/C/W135 meningococcal polysaccharide vaccine in Burkina Faso, 2003. Vaccine 25(Suppl 1A92-A96.
72. Reingold AL, Broome CV, Hightower AW, Ajello GW, Bolan GA, Adamsbaum C, Jones EE, Phillips C, Tiendrebeogo H, Yada A (1985) Age-specific differences in duration of clinical protection after vaccination with meningococcal polysaccharide A vaccine. Lancet 2:114-118.
73. MacLennan J, Obaro S, Deeks J,Williams D, Pais L, Carlone G, Moxon R, Greenwood B (1999) Immune response to revaccination with meningococcal A and C polysaccharides in Gambian children following repeated immunisation during early childhood. Vaccine 17:3086-3093.
74. Berry DS, Lynn F, Lee CH, Frasch CE, Bash MC (2002) Effect of O acetylation of Neisseria meningitidis serogroup A capsular polysaccharide on development of functional immune responses. Infect. Immun. 70:3707-3713.
75. Girard MP, Preziosi MP, Aguado MT, Kieny MP (2006) A review of vaccine research and development: Meningococcal disease. Vaccine 24:4692-4700.
76. Jodar L, Feavers IM, Salisbury D, Granoff DM (2002) Development of vaccines against meningococcal disease. Lancet 359:1499-1508.
77. LaForce FM, Konde K, Viviani S, Preziosi MP (2007) The Meningitis Vaccine Project. Vaccine 25(Suppl 1):A97-100.
78. Robbins JB, Schneerson R, Gotschlich EC (2000) A rebuttal: Epidemic and endemic meningococcal meningitis in sub-Saharan Africa can be prevented now by routine immunization with group A meningococcal capsular polysaccharide vaccine. Pediatr. Infect. Dis. J. 19:945-953.
79. Patel M, Lee CK (2005) Polysaccharide vaccines for preventing serogroup A meningococcal meningitis. Cochrane. Database Syst. Rev. CD001093.
80. Lieberman JM, Chiu SS, Wong VK, Partidge S, Chang SJ, Chiu CY, Gheesling LL, Carlone GM, Ward JI (1996) Safety and immunogenicity of a serogroups A/C Neisseria meningitidis oligosaccharide-protein conjugate vaccine in young children. A randomized controlled trial. JAMA 275:1499-1503.
81. Fairley CK, Begg N, Borrow R, Fox AJ, Jones DM, Cartwright K (1996) Conjugate meningococcal serogroup A and C vaccine: Reactogenicity and immunogenicity in United Kingdom infants. J. Infect. Dis. 174:1360-1363.
82. Leach A, Twumasi PA, Kumah S, Banya WS, Jaffar S, Forrest BD, Granoff DM, LiButti DE, Carlone GM, Pais LB, Broome CV, Greenwood BM (1997) Induction of immunologic memory in Gambian children by vaccination in infancy with a group A plus group C meningococcal polysaccharide-protein conjugate vaccine. J. Infect. Dis. 175:200-204.
83. MacLennan J, Obaro S, Deeks J, Lake D, Elie C, Carlone G, Moxon ER, Greenwood B (2001) Immunologic memory 5 years after meningococcal A/C conjugate vaccination in infancy. J. Infect. Dis. 183:97-104.
84. Campagne G, Garba A, Fabre P, Schuchat A, Ryall R, Boulanger D, Bybel M, Carlone G, Briantais P, Ivanoff B, Xerri B, Chippaux JP (2000) Safety and immunogenicity of three doses of a Neisseria meningitidis A + C diphtheria conjugate vaccine in infants from Niger. Pediatr. Infect. Dis. J. 19:144-150.
85. Rennels M, King JJ, Ryall R, Papa T, Froeschle J (2004) Dosage escalation, safety and immunogenicity study of four dosages of a tetravalent meninogococcal polysaccharide diphtheria toxoid conjugate vaccine in infants. Pediatr. Infect. Dis. J. 23:429-435.
86. Joseph H, Ryall R, Bybel M, Papa T, MacLennan J, Buttery J, Borrow R (2003) Immunogenicity and immunological priming of the serogroup a portion of a bivalent meningococcal A/C conjugate vaccine in 2-year-old children. J. Infect. Dis. 187: 1142-1146.
87. Anderson P, Pichichero M, Edwards K, Porch CR, Insel R (1987) Priming and induction of Haemophilus influenzae type b capsular antibodies in early infancy by Dpo20, an oligosaccharide-protein conjugate vaccine. J. Pediatr. 111:644-650.
88. Jennings HJ, Lugowski C (1981) Immunochemistry of groups A, B, and C meningococcal polysaccharide-tetanus toxoid conjugates. J. Immunol. 127:1011-1018.
89. Jessouroun E, Da Silveira IAF, Bastos RC, Frasch CE, Lee CJ (2005) Process for preparing polysaccharide-protein conjugate vaccines Patent No. WO/2005/037320.
90. Kshirsagar N, Mur N, Thatte U, Gogtay N, Viviani S, Preziosi MP, Elie C, Findlow H, Carlone G, Borrow R, Parulekar V, Plikaytis B, Kulkarni P, Imbault N, LaForce FM (2007) Safety, immunogenicity, and antibody persistence of a new meningococcal group A conjugate vaccine in healthy Indian adults. Vaccine 25(Suppl 1A101-A107.
91. Gray SJ, Trotter CL, Ramsay ME, Guiver M, Fox AJ, Borrow R, Mallard RH, Kaczmarski EB (2006) Epidemiology of meningococcal disease in England and Wales 1993/94 to 2003/04: Contribution and experiences of the Meningococcal Reference Unit. J. Med. Microbiol. 55:887-896.
92. Ashton FE, Ryan JA, Borczyk A, Caugant DA, Mancino L, Huang D (1991) Emergence of a virulent clone of Neisseria meningitidis serotype 2a that is associated with meningococcal group C disease in Canada. J. Clin. Microbiol. 29:2489-2493.
93. Borrow R, Andrews N, Goldblatt D, Miller E (2001) Serological basis for use of meningococcal serogroup C conjugate vaccines in the United Kingdom: Reevaluation of correlates of protection. Infect. Immun. 69:1568-1573.
94. Richmond P, Goldblatt D, Fusco PC, Fusco JD, Heron I, Clark S, Borrow R, Michon F (1999) Safety and immunogenicity of a new Neisseria meningitidis serogroup C-tetanus toxoid conjugate vaccine in healthy adults. Vaccine 18:641-646.
95. Borrow R, Southern J, Andrews N, Peake N, Rahim R, Acuna M, Martin S, Miller E, Kaczmarski E (2001) Comparison of antibody kinetics following meningococcal serogroup C conjugate vaccine between healthy adults previously vaccinated with meningococcal A/C polysaccharide vaccine and vaccine-naive controls. Vaccine 19:3043-3050.
96. Richmond P, Kaczmarski E, Borrow R, Findlow J, Clark S, McCann R, Hill J, Barker M, Miller E (2000) Meningococcal C polysaccharide vaccine induces immunologic hyporesponsiveness in adults that is overcome by meningococcal C conjugate vaccine. J. Infect. Dis. 181:761-764.
97. Richmond P, BorrowR, Goldblatt D, FindlowJ, Martin S, Morris R, Cartwright K, Miller E (2001) Ability of 3 different meningococcal C conjugate vaccines to induce immunologic memory after a single dose in UK toddlers. J. Infect. Dis. 183:160-163.
98. MacLennan JM, Shackley F, Heath PT, Deeks JJ, Flamank C, Herbert M, Griffiths H, Hatzmann E, Goilav C, Moxon ER (2000) Safety, immunogenicity, and induction of immunologic memory by a serogroup C meningococcal conjugate vaccine in infants: A randomized controlled trial. JAMA 283:2795-2801.
99. Bramley JC, Hall T, Finn A, Buttery RB, Elliman D, Lockhart S, Borrow R, Jones IG (2001) Safety and immunogenicity of three lots of meningococcal serogroup C conjugate vaccine administered at 2, 3 and 4 months of age. Vaccine 19:2924-2931.
100. Richmond P, Borrow R, Miller E, Clark S, Sadler F, Fox A, Begg N, Morris R, Cartwright K (1999) Meningococcal serogroup C conjugate vaccine is immunogenic in infancy and primes for memory. J. Infect. Dis. 179:1569-1572.
101. Borrow R, Longworth E, Gray SJ, Kaczmarski EB (2000) Prevalence of de-O-acetylated serogroup C meningococci before the introduction of meningococcal serogroup C conjugate vaccines in the United Kingdom. FEMS Immunol. Med. Microbiol. 28:189-191.
102. Glode MP, Lewin EB, Sutton A, Le CT, Gotschlich EC, Robbins JB (1979) Comparative immunogenicity of vaccines prepared from capsular polysaccharides of group C Neisseria meningitidis O-acetyl-positive and O-acetyl-negative variants and Escherichia coli K92 in adult volunteers. J. Infect. Dis. 139:52-59.
103. Steinhoff MC, Lewin EB, Gotschlich EC, Robbins JB (1981) Group C Neisseria meningitidis variant polysaccharide vaccines in children. Infect. Immun. 34:144-146.
104. Richmond P, Borrow R, Findlow J, Martin S, Thornton C, Cartwright K, Miller E (2001) Evaluation of De-O-acetylated meningococcal C polysaccharide-tetanus toxoid conjugate vaccine in infancy: Reactogenicity, immunogenicity, immunologic priming, and bactericidal activity against O-acetylated and De-O-acetylated serogroup C strains. Infect. Immun. 69:2378-2382.
105. Rubinstein LJ, Garcia-Ojeda PA, Michon F, Jennings HJ, Stein KE (1998) Murine immune responses to Neisseria meningitidis group C capsular polysaccharide and a thymus-dependent toxoid conjugate vaccine. Infect. Immun. 66:5450-5456.
106. Michon F, Huang CH, Farley EK, Hronowski L, Di J, Fusco PC (2000) Structure activity studies on group C meningococcal polysaccharide-protein conjugate vaccines: Effect of O-acetylation on the nature of the protective epitope. Dev. Biol. (Basel) 103:151-160.
107. Miller E, Salisbury D, Ramsay M (2001) Planning, registration, and implementation of an immunisation campaign against meningococcal serogroup C disease in the UK: A success story. Vaccine 20(Suppl 1):S58-S67.
108. Balmer P, Borrow R, Miller E (2002) Impact of meningococcal C conjugate vaccine in the UK. J. Med. Microbiol. 51:717-722.
109. Larrauri A, Cano R, Garcia M, Mateo S (2005) Impact and effectiveness of meningococcal C conjugate vaccine following its introduction in Spain. Vaccine 23:4097-4100.
110. De Wals P, Deceuninck G, Boulianne N, De Serres G (2004) Effectiveness of a mass immunization campaign using serogroup C meningococcal conjugate vaccine. JAMA 292:2491-2494.
111. Trotter CL, Andrews NJ, Kaczmarski EB, Miller E, Ramsay ME (2004) Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction. Lancet 364:365-367.
112. Trotter CL, McVernon J, Andrews NJ, Burrage M, Ramsay ME (2003) Antibody to Haemophilus influenzae type b after routine and catch-up vaccination. Lancet 361: 1523-1524.
113. Borrow R, Goldblatt D, Finn A, Southern J, Ashton L, Andrews N, Lal G, Riley C, Rahim R, Cartwright K, Allan G, Miller E (2003) Immunogenicity of, and immunologic memory to, a reduced primary schedule of meningococcal C-tetanus toxoid conjugate vaccine in infants in the United Kingdom. Infect. Immun. 71:5549-5555.
114. Sexton K, Lennon D, Oster P, Crengle S, Martin D, Mulholland K, Percival T, Reid S, Stewart J, O'Hallahan J (2004) The New Zealand Meningococcal Vaccine Strategy: A tailor-made vaccine to combat a devastating epidemic. N. Z. Med. J. 117:U1015.
115. Tondella ML, Popovic T, Rosenstein NE, Lake DB, Carlone GM, Mayer LW, Perkins BA (2000) Distribution of Neisseria meningitidis serogroup B serosubtypes and serotypes circulating in the United States. The Active Bacterial Core Surveillance Team. J. Clin. Microbiol. 38:3323-3328.
116. Finne J, Leinonen M, Makela PH (1983) Antigenic similarities between brain components and bacteria causing meningitis. Implications for vaccine development and pathogenesis. Lancet 2:355-357.
117. Devi SJN, Robbins JB, Schneerson R (1991) Antibodies to poly[(2-8)-falphag-Nacetylneuraminic acid] and poly[(2-9)-falphag-N-acetylneuraminic acid] are elicited by immunization of mice with Escherichia coli K92 conjugates: Potential vaccines for GroupsBandCmeningococci and E. coli K1. Proc.Natl. Acad. Sci. U.S.A. 88:7175-7179.
118. Stein DM, Robbins J, Miller MA, Lin FY, Schneerson R (2006) Are antibodies to the capsular polysaccharide of Neisseria meningitidis group B and Escherichia coli K1 associated with immunopathology? Vaccine 24:221-228.
119. Jennings HJ, Roy R, Gamian A (1986) Induction of meningococcal group B polysaccharide-specific IgG antibodies in mice by using an N-propionylated B polysaccharide-tetanus toxoid conjugate vaccine. J. Immunol. 137:1708-1713.
120. Jennings HJ, Gamian A, Ashton FE (1987) N-propionylated group B meningococcal polysaccharide mimics a unique epitope on group B Neisseria meningitidis. J. Exp. Med. 165:1207-1211.
121. Jennings HJ (1988) Chemically modified capsular polysaccharides as vaccines. Adv. Exp. Med. Biol. 228:495-550.
122. Granoff DM, Bartoloni A, Ricci S, Gallo E, Rosa D, Ravenscroft N, Guarnieri V, Seid RC, Shan A, Usinger WR, Tan S, McHugh YE, Moe GR (1998) Bactericidal monoclonal antibodies that define unique meningococcal B polysaccharide epitopes that do not cross-react with human polysialic acid. J. Immunol. 160:5028-5036.
123. Coquillat D, Bruge J, Danve B, Latour M, Hurpin C, Schulz D, Durbec P, Rougon G (2001) Activity and cross-reactivity of antibodies induced in mice by immunization with a group B meningococcal conjugate. Infect. Immun. 69:7130-7139.
124. Moe GR, Dave A, Granoff DM (2005) Epitopes recognized by a nonautoreactive murine anti-N-propionyl meningococcal group B polysaccharide monoclonal antibody. Infect. Immun. 73:2123-2128.
125. Pon RA, Lussier M, Yang QL, Jennings HJ (1997) N-Propionylated group B meningococcal polysaccharide mimics a unique bactericidal capsular epitope in group B Neisseria meningitidis. J. Exp. Med. 185:1929-1938.
126. Fusco PC, Michon F, Tai JY, Blake MS (1997) Preclinical evaluation of a novel group B meningococcal conjugate vaccine that elicits bactericidal activity in both mice and nonhuman primates. J. Infect. Dis. 175:364-372.
127. Moore S, Farley EK, Fusco PC, Michon F (2007) Specificity of the immune response to a modified group B meningococcal polysaccharide conjugate vaccine. Clin. Vaccine Immunol. 14:106-109.
128. Bruge J, Bouveret-Le-Cam N, Danve B, Rougon G, Schulz D (2004) Clinical evaluation of a group B meningococcal N-propionylated polysaccharide conjugate vaccine in adult, male volunteers. Vaccine 22:1087-1096.
129. Plested JS, Harris SL, Wright JC, Coull PA, Makepeace K, Gidney MA, Brisson JR, Richards JC, Granoff DM, Moxon ER (2003) Highly conserved Neisseria meningitidis inner-core lipopolysaccharide epitope confers protection against experimental meningococcal bacteremia. J. Infect. Dis. 187:1223-1234.
130. Plested JS, Makepeace K, Jennings MP, Gidney MA, Lacelle S, Brisson J, Cox AD, Martin A, Bird AG, Tang CM, Mackinnon FM, Richards JC, Moxon ER (1999) Conservation and accessibility of an inner core lipopolysaccharide epitope of Neisseria meningitidis. Infect. Immun. 67:5417-5426.
131. Verheul AF, Boons GJ, Van der Marel GA, Van Boom JH, Jennings HJ, Snippe H, Verhoef J, Hoogerhout P, Poolman JT (1991) Minimal oligosaccharide structures required for induction of immune responses against meningococcal immunotype L1, L2, and L3,7,9 lipopolysaccharides determined by using synthetic oligosaccharide-protein conjugates. Infect. Immun. 59:3566-3573.
132. Perrett KP, Pollard AJ (2005) Towards an improved serogroup B Neisseria meningitidis vaccine. Expert. Opin. Biol. Ther. 5:1611-1625.
133. Harrison LH (2006) Prospects for vaccine prevention of meningococcal infection. Clin. Microbiol. Rev. 19:142-164.
134. Sierra GV, Campa HC, Varcacel NM, Garcia IL, Izquierdo PL, Sotolongo PF, Casanueva GV, Rico CO, Rodriguez CR, TerryMH (1991) Vaccine against group B Neisseria meningitidis: Protection trial and mass vaccination results in Cuba. NIPH Ann. 14:195-207.
135. Oster P, Lennon D, O'Hallahan J, Mulholland K, Reid S, Martin D (2005) MeNZB: A safe and highly immunogenic tailor-made vaccine against the New Zealand Neisseria meningitidis serogroup B disease epidemic strain. Vaccine 23:2191-2196.
136. Bjune G, Hoiby EA, Gronnesby JK, Arnesen O, Fredriksen JH, Halstensen A, Holten E, Lindbak AK, Nokleby H, Rosenqvist E, Solberg LK, Closs O, Eng J, Froholm LO, Lystad A, Bakketeig LS, Hareide B (1991) Effect of outer membrane vesicle vaccine against group B meningococcal disease in Norway. Lancet 338:1093-1096.
137. Bilukha OO, Rosenstein N (2005) Prevention and control of meningococcal disease. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm. Rep. 54:1-21.
138. Keyserling H, Papa T, Koranyi K, Ryall R, Bassily E, Bybel MJ, Sullivan K, Gilmet G, Reinhardt A (2005) Safety, immunogenicity, and immune memory of a novel meningococcal (groups A, C, Y, and W-135) polysaccharide diphtheria toxoid conjugate vaccine (MCV-4) in healthy adolescents. Arch. Pediatr. Adolesc. Med. 159:907-913.
139. Rennels M, King JJ, Ryall R, Papa T, Froeschle J (2004) Dosage escalation, safety and immunogenicity study of four dosages of a tetravalent meninogococcal polysaccharide diphtheria toxoid conjugate vaccine in infants. Pediatr. Infect. Dis. J. 23:429-435.
140. Pichichero M, Casey J, Blatter M, Rothstein E, Ryall R, Bybel M, Gilmet G, Papa T (2005) Comparative trial of the safety and immunogenicity of quadrivalent (A, C, Y, W-135) meningococcal polysaccharide-diphtheria conjugate vaccine versus quadrivalent polysaccharide vaccine in two-to ten-year-old children. Pediatr. Infect. Dis. J. 24:57-62.
141. Sanofi Pasteur (2007) Menactra meningococcal conjugate vaccine approved for use in children 2 years through to 10 years of age. Available at: http://www.vaccineplace.com/docs/MENACTRA_FDA_APPROVAL_181007_ENG.pdf.
142. Snape MD, Perrett KP, Ford KJ, John TM, Pace D, Yu LM, Langley JM, McNeil S, Dull PM, Ceddia F, Anemona A, Halperin SA, Dobson S, Pollard AJ (2008) Immunogenicity of a tetravalent meningococcal glycoconjugate vaccine in infants-A randomized controlled trial. JAMA 299:173-184.
143. Anon (2008) Novartis Menveow vaccine shows superior immune response against four types of meningitis disease in pivotal phase III trial. Available at: http://www.novartis.com/newsroom/media-releases/en/2008/1180471.shtml.
144. Trotter CL, Ramsay ME (2007) Vaccination against meningococcal disease in Europe: Review and recommendations for the use of conjugate vaccines. FEMS Microbiol. Rev. 31:101-107.
145. Anon (2007) Pneumococcal conjugate vaccine for childhood immunization-WHO position paper. Wkly. Epidemiol. Rec. 82:93-104.
146. Low DE (2005) Changing trends in antimicrobial-resistant pneumococci: It's not all bad news. Clin. Infect. Dis. 41(Suppl 4S228-S233.
147. Lee CJ (1999) Advances in pneumococcal vaccines. Infect. Med. 16:596-612.
148. Anon (2007) Pneumococcal disease. Available at: www.cdc.gov/vaccines/pubs/pinkbook/downloads/pneumo.pdf.
149. O'Brien KL, Moulton LH, Reid R,Weatherholtz R, Oski J, Brown L, Kumar G, Parkinson A, Hu D, Hackell J, Chang I, Kohberger R, Siber G, Santosham M (2003) Efficacy and safety of seven-valent conjugate pneumococcal vaccine in American Indian children: Group randomised trial. Lancet 362:355-361.
150. Robbins JB, Austrian R, Lee CJ, Rastogi SC, Schiffman G, Henrichsen J, Makela PH, Broome CV, Facklam RR, Tiesjema RH, Parke JC (1983) Considerations for formulating the second-generation pneumococcal capsular polysaccharide vaccine with emphasis on the cross-reactive types within groups. J. Infect. Dis. 148:1136-1159.
151. Shapiro ED, Berg AT, Austrian R, Schroeder D, Parcells V, Margolis A, Adair RK, Clemens JD (1991) The protective efficacy of polyvalent pneumococcal polysaccharide vaccine. N. Engl. J. Med. 325:1453-1460.
152. Melegaro A, Edmunds WJ (2004) The 23-valent pneumococcal polysaccharide vaccine. Part I. Efficacy of PPV in the elderly: A comparison of meta-analyses. Eur. J. Epidemiol. 19:353-363.
153. Jodar L, Butler J, Carlone G, Dagan R, Goldblatt D, Kayhty H, Klugman K, Plikaytis B, Siber G, Kohberger R, Chang I, Cherian T (2003) Serological criteria for evaluation and licensure of new pneumococcal conjugate vaccine formulations for use in infants. Vaccine 21:3265-3272.
154. World Health Organization (2005) Recommendations for the production and control of pneumococcal conjugate vaccines. WHO Technical Report Series. 927:64-98.
155. Butler JC (1997) Epidemiology of pneumococcal serotypes and conjugate vaccine formulations. Microb. Drug Resist. 3:125-129.
156. Farrell DJ, Jenkins SG, Reinert RR (2004) Global distribution of Streptococcus pneumoniae serotypes isolated from paediatric patients during 1999-2000 and the in vitro efficacy of telithromycin and comparators. J. Med. Microbiol. 53:1109-1117.
157. Oosterhuis-Kafeja F, Beutels P, Van Damme P (2007) Immunogenicity, efficacy, safety and effectiveness of pneumococcal conjugate vaccines (1998-2006). Vaccine 25: 2194-2212.
158. Daum RS, Hogerman D, Rennels MB, Bewley K, Malinoski F, Rothstein E, Reisinger K, Block S, Keyserling H, Steinhoff M (1997) Infant immunization with pneumococcal CRM197 vaccines: Effect of saccharide size on immunogenicity and interactions with simultaneously administered vaccines. J. Infect. Dis. 176:445-455.
159. Eskola J, KilpiT,Palmu A, Jokinen J, Haapakoski J, Herva E,Takala A,Kayhty H, KarmaP, Kohberger R, Siber G, Makela PH (2001) Efficacy of a pneumococcal conjugate vaccine against acute otitis media. N. Engl. J. Med. 344:403-409.
160. Dagan R, Eskola J, Leclerc C, Leroy O (1998) Reduced response to multiple vaccines sharing common protein epitopes that are administered simultaneously to infants. Infect. Immun. 66:2093-2098.
161. Dagan R, Goldblatt D, Maleckar JR, Yaich M, Eskola J (2004) Reduction of antibody response to an 11-valent pneumococcal vaccine coadministered with a vaccine containing acellular pertussis components. Infect. Immun. 72:5383-5391.
162. Lucero MG, Puumalainen T, Ugpo JM,Williams G, Kayhty H, Nohynek H (2004) Similar antibody concentrations in Filipino infants at age 9 months, after 1 or 3 doses of an adjuvanted, 11-valent pneumococcal diphtheria/tetanus-conjugated vaccine: A randomized controlled trial. J. Infect. Dis. 189:2077-2084.
163. Cutts FT, Zaman SM, Enwere G, Jaffar S, Levine OS, Okoko JB, Oluwalana C, Vaughan A, Obaro SK, Leach A, McAdam KP, Biney E, Saaka M, Onwuchekwa U, Yallop F, Pierce NF, Greenwood BM, Adegbola RA (2005) Efficacy of nine-valent pneumococcal conjugate vaccine against pneumonia and invasive pneumococcal disease in the Gambia: Randomised, double-blind, placebo-controlled trial. Lancet 365: 1139-1146.
164. Dagan R, Kayhty H, Wuorimaa T, Yaich M, Bailleux F, Zamir O, Eskola J (2004) Tolerability and immunogenicity of an eleven valent mixed carrier Streptococcus pneumoniae capsular polysaccharide-diphtheria toxoid or tetanus protein conjugate vaccine in Finnish and Israeli infants. Pediatr. Infect. Dis. J. 23:91-98.
165. Black S, Shinefield H, Fireman B, Lewis E, Ray P, Hansen JR, Elvin L, Ensor KM, Hackell J, Siber G, Malinoski F, Madore D, Chang I, Kohberger R, Watson W, Austrian R, Edwards K (2000) Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group. Pediatr. Infect. Dis. J. 19:187-195.
166. Choo S, Seymour L, Morris R, Quataert S, Lockhart S, Cartwright K, Finn A (2000) Immunogenicity and reactogenicity of a pneumococcal conjugate vaccine administered combined with a haemophilus influenzae type B conjugate vaccine in United Kingdom infants. Pediatr. Infect. Dis. J. 19:854-862.
167. Anon (2005) Direct and indirect effects of routine vaccination of children with 7-valent pneumococcal conjugate vaccine on incidence of invasive pneumococcal disease-United States, 1998-2003. MMWR Morb. Mortal. Wkly. Rep. 54:893-897.
168. Kilpi T, Ahman H, Jokinen J, Lankinen KS, Palmu A, Savolainen H, Gronholm M, Leinonen M, Hovi T, Eskola J, Kayhty H, Bohidar N, Sadoff JC, Makela PH (2003) Protective efficacy of a second pneumococcal conjugate vaccine against pneumococcal acute otitis media in infants and children: Randomized, controlled trial of a 7-valent pneumococcal polysaccharide-meningococcal outer membrane protein complex conjugate vaccine in 1666 children. Clin. Infect. Dis. 37:1155-1164.
169. Fletcher MA, Fritzell B (2007) Brief review of the clinical effectiveness of PREVENAR against otitis media. Vaccine 25:2507-2512.
170. Palmu AA, Verho J, Jokinen J, Karma P, Kilpi TM (2004) The seven-valent pneumococcal conjugate vaccine reduces tympanostomy tube placement in children. Pediatr. Infect. Dis. J. 23:732-738.
171. Palmu AA, Jokinen JT, Kaijalainen T, Leinonen M, Karma P, Kilpi TM (2005) Association of clinical signs and symptoms with pneumococcal acute otitis media by serotype-implications for vaccine effect. Clin. Infect. Dis. 40:52-57.
172. O'Brien KL, David AB, Chandran A, Moulton LH, Reid R,Weatherholtz R, SantoshamM (2008) Randomized, controlled trial efficacy of pneumococcal conjugate vaccine against otitis media among Navajo and White Mountain Apache infants. Pediatr. Infect. Dis. J. 27:71-73.
173. Dagan R, Givon-Lavi N, Zamir O, Fraser D (2003) Effect of a nonavalent conjugate vaccine on carriage of antibiotic-resistant Streptococcus pneumoniae in day-care centers. Pediatr. Infect. Dis. J. 22:532-540.
174. Choo S, Zhang Q, Seymour L, Akhtar S, Finn A (2000) Primary and booster salivary antibody responses to a 7-valent pneumococcal conjugate vaccine in infants. J. Infect. Dis. 182:1260-1263.
175. Bogaert D,Veenhoven RH, Ramdin R, Luijendijk IH, RijkersGT, Sanders EA, de Groot R, Hermans PW (2005) Pneumococcal conjugate vaccination does not induce a persisting mucosal IgA response in children with recurrent acute otitis media. Vaccine 23: 2607-2613.
176. Hammitt LL, Bruden DL, Butler JC, Baggett HC, Hurlburt DA, Reasonover A, Hennessy TW (2006) Indirect effect of conjugate vaccine on adult carriage of Streptococcus pneumoniae: An explanation of trends in invasive pneumococcal disease. J. Infect. Dis. 193:1487-1494.
177. Byington CL, Samore MH, Stoddard GJ, Barlow S, Daly J, Korgenski K, Firth S, Glover D, Jensen J, Mason EO, Shutt CK, Pavia AT (2005) Temporal trends of invasive disease due to Streptococcus pneumoniae among children in the intermountain west: Emergence of nonvaccine serogroups. Clin. Infect. Dis. 41:21-29.
178. Peters TR, Poehling KA (2007) Invasive pneumococcal disease: The target is moving. JAMA 297:1825-1826.
179. Law MR, Palomaki G, Alfirevic Z, Gilbert R, Heath P, McCartney C, Reid T, Schrag S (2005) The prevention of neonatal group B streptococcal disease: A report by a working group of the Medical Screening Society. J. Med. Screen. 12:60-68.
180. Baker CJ, Edwards MS (2003) Group B streptococcal conjugate vaccines. Arch. Dis. Child 88:375-378.
181. Schuchat A, Wenger JD (1994) Epidemiology of group B streptococcal disease. Risk factors, prevention strategies, and vaccine development. Epidemiol. Rev. 16:374-402.
182. Schrag S, Gorwitz R, Fultz-Butts K, Schuchat A (2002) Prevention of perinatal group B streptococcal disease. Revised guidelines from CDC. MMWR Recomm. Rep. 51:1-22.
183. Schuchat A, Oxtoby M, Cochi S, Sikes RK, Hightower A, Plikaytis B, Broome CV (1990) Population-based risk factors for neonatal group B streptococcal disease: Results of a cohort study in metropolitan Atlanta. J. Infect. Dis. 162:672-677.
184. Anon (2005) Early-onset and late-onset neonatal group B streptococcal disease-United States, 1996-2004. MMWR Morb. Mortal. Wkly. Rep. 54:1205-1208.
185. Schrag SJ, Zywicki S, Farley MM, Reingold AL, Harrison LH, Lefkowitz LB, Hadler JL, Danila R, Cieslak PR, Schuchat A (2000) Group B streptococcal disease in the era of intrapartum antibiotic prophylaxis. N. Engl. J. Med. 342:15-20.
186. Wessels MR, DiFabio JL, Benedi VJ, Kasper DL, Michon F, Brisson JR, Jelinkova J, Jennings HJ (1991) Structural determination and immunochemical characterization of the type V group B Streptococcus capsular polysaccharide. J. Biol. Chem. 266: 6714-6719.
187. Hervas JA, Benedi VJ (1993) Neonatal sepsis caused by a new group B streptococcal serotype (type V). J. Pediatr. 123:839.
188. FarleyMM (2001) Group B streptococcal disease in nonpregnant adults. Clin. Infect. Dis. 33:556-561.
189. Harrison LH, Elliott JA, Dwyer DM, Libonati JP, Ferrieri P, Billmann L, Schuchat A (1998) Serotype distribution of invasive group B streptococcal isolates in Maryland: Implications for vaccine formulation. Maryland Emerging Infections Program. J. Infect. Dis. 177:998-1002.
190. Zaleznik DF, Rench MA, Hillier S, Krohn MA, Platt R, Lee ML, Flores AE, Ferrieri P, Baker CJ (2000) Invasive disease due to group B Streptococcus in pregnant women and neonates from diverse population groups. Clin. Infect. Dis. 30:276-281.
191. Baker CJ, Rench MA, Paoletti LC, Edwards MS (2007) Dose-response to type V group B streptococcal polysaccharide-tetanus toxoid conjugate vaccine in healthy adults. Vaccine 25:55-63.
192. Baker CJ, Kasper DL (1976) Correlation of maternal antibody deficiency with susceptibility to neonatal group B streptococcal infection. N. Engl. J. Med. 294:753-756.
193. Wessels MR, Paoletti LC, Kasper DL, DiFabio JL, Michon F, Holme K, Jennings HJ (1990) Immunogenicity in animals of a polysaccharide-protein conjugate vaccine against type III group B Streptococcus. J. Clin. Invest 86:1428-1433.
194. Englund JA, Glezen WP (2003) Maternal immunization with Haemophilus influenzae type b vaccines in different populations. Vaccine 21:3455-3459.
195. Jennings HJ, Katzenellenbogen E, Lugowski C, Kasper DL (1983) Structure of native polysaccharide antigens of type Ia and type Ib group B Streptococcus. Biochemistry 22:1258-1264.
196. Jennings HJ, Rosell KG, Katzenellenbogen E, Kasper DL (1983) Structural determination of the capsular polysaccharide antigen of type II group B Streptococcus. J. Biol. Chem. 258:1793-1798.
197. Wessels MR, Pozsgay V, Kasper DL, Jennings HJ (1987) Structure and immunochemistry of an oligosaccharide repeating unit of the capsular polysaccharide of type III group B Streptococcus. A revised structure for the type III group B streptococcal polysaccharide antigen. J. Biol. Chem. 262:8262-8267.
198. Di Fabio JL, Michon F, Brisson JR, Benedi VJ, Wessels MR, Kaspar DL, Jennings HJ (1989) Structure of the capsular polysaccharide antigen of Type IV group B Streptococcus. Can. J. Chem. 67:877-882.
199. Kogan G, Uhrin D, Brisson JR, Paoletti LC, Kaspar DL, von Hunolstein C, Orefici G, Jennings HJ (1994) Structure of the type VI group B Streptococcus capsular polysaccharide determined by high resolution NMR spectroscopy. J. Carbohydr. Chem. 13:1071-1078.
200. Lewis AL, Nizet V, Varki A (2004) Discovery and characterization of sialic acid O-acetylation in group B Streptococcus. Proc. Natl. Acad. Sci. U.S.A. 101:11123-11128.
201. Baker CJ, Rench MA, Edwards MS, Carpenter RJ, Hays BM, Kasper DL (1988) Immunization of pregnant women with a polysaccharide vaccine of group B streptococcus. N. Engl. J. Med. 319:1180-1185.
202. Wessels MR, Munoz A, Kasper DL (1987) A model of high-affinity antibody binding to type III group B Streptococcus capsular polysaccharide. Proc. Natl. Acad. Sci. U.S.A. 84:9170-9174.
203. Brisson JR, Uhrinova S, Woods RJ, vanderZwan M, Jarrell HC, Paoletti LC, Kasper DL, Jennings HJ (1997) NMR and molecular dynamics studies of the conformational epitope of the type III group B Streptococcus capsular polysaccharide and derivatives. Biochemistry 36:3278-3292.
204. Kasper DL, Paoletti LC,Wessels MR, Guttormsen HK, Carey VJ, Jennings HJ, Baker CJ (1996) Immune response to type III group B streptococcal polysaccharide-tetanus toxoid conjugate vaccine. J. Clin. Invest. 98:2308-2314.
205. Baker CJ, Paoletti LC, Wessels MR, Guttormsen HK, Rench MA, Hickman ME, Kasper DL (1999) Safety and immunogenicity of capsular polysaccharide-tetanus toxoid conjugate vaccines for group B streptococcal types Ia and Ib. J. Infect. Dis. 179:142-150.
206. Baker CJ, Paoletti LC, Rench MA, Guttormsen HK, Carey VJ, Hickman ME, Kasper DL (2000) Use of capsular polysaccharide-tetanus toxoid conjugate vaccine for type II group B Streptococcus in healthy women. J. Infect. Dis. 182:1129-1138.
207. Baker CJ, Paoletti LC, Rench MA, Guttormsen HK, Edwards MS, Kasper DL (2004) Immune response of healthy women to 2 different group B streptococcal type V capsular polysaccharide-protein conjugate vaccines. J. Infect. Dis. 189:1103-1112.
208. Baker CJ, Rench MA, Fernandez M, Paoletti LC, Kasper DL, Edwards MS (2003) Safety and immunogenicity of a bivalent group B streptococcal conjugate vaccine for serotypes II and III. J. Infect. Dis. 188:66-73.
209. Baker CJ, Rench MA, McInnes P (2003) Immunization of pregnant women with group B streptococcal type III capsular polysaccharide-tetanus toxoid conjugate vaccine. Vaccine 21:3468-3472.
210. Palazzi DL, Rench MA, Edwards MS, Baker CJ (2004) Use of type V group B streptococcal conjugate vaccine in adults 65-85 years old. J. Infect. Dis. 190:558-564.
211. Edwards MS (2006) Issues of antimicrobial resistance in group B streptococcus in the era of intrapartum antibiotic prophylaxis. Semin. Pediatr. Infect. Dis. 17:149-152.
212. Crump JA, Luby SP, Mintz ED (2004) The global burden of typhoid fever. Bull. World Health Organ. 82:346-353.
213. Sinha A, Sazawal S, Kumar R, Sood S, Reddaiah VP, Singh B, Rao M, Naficy A, Clemens JD, Bhan MK (1999) Typhoid fever in children aged less than 5 years. Lancet 354:734-737.
214. Lin FY, Vo AH, Phan VB, Nguyen TT, Bryla D, Tran CT, Ha BK, Dang DT, Robbins JB (2000) The epidemiology of typhoid fever in the Dong Thap Province, Mekong Delta region of Vietnam. Am. J. Trop. Med. Hyg. 62:644-648.
215. Szu SC, Li XR, Stone AL, Robbins JB (1991) Relation between structure and immunologic properties of the Vi capsular polysaccharide. Infect. Immun. 59:4555-4561.
216. Robbins JD, Robbins JB (1984) Reexamination of the protective role of the capsular polysaccharide (Vi antigen) of Salmonella typhi. J. Infect. Dis. 150:436-449.
217. Fraser A, Goldberg E, Acosta CJ, Paul M, Leibovici L (2007) Vaccines for preventing typhoid fever. Cochrane. Database Syst. Rev. CD001261.
218. Rowe B, Ward LR, Threlfall EJ (1997) Multidrug-resistant Salmonella typhi: A worldwide epidemic. Clin. Infect. Dis. 24(Suppl 1S106-S109.
219. Lebacq E (2001) Comparative tolerability and immunogenicity of Typherix or Typhim Vi in healthy adults: 0, 12-month and 0, 24-month administration. BioDrugs 15(Suppl 1):5-12.
220. Fraser A, Paul M, Goldberg E, Acosta CJ, Leibovici L (2007) Typhoid fever vaccines: Systematic review and meta-analysis of randomised controlled trials. Vaccine 25: 7848-7857.
221. Keitel WA, Bond NL, Zahradnik JM, Cramton TA, Robbins JB (1994) Clinical and serological responses following primary and booster immunization with Salmonella typhi Vi capsular polysaccharide vaccines. Vaccine 12:195-199.
222. Klugman KP, Koornhof HJ, Robbins JB, Le Cam NN (1996) Immunogenicity, efficacy and serological correlate of protection of Salmonella typhi Vi capsular polysaccharide vaccine three years after immunization. Vaccine 14:435-438.
223. Mai NL, Phan VB, Vo AH, Tran CT, Lin FY, Bryla DA, Chu C, Schiloach J, Robbins JB, Schneerson R, Szu SC (2003) Persistent efficacy of Vi conjugate vaccine against typhoid fever in young children. N. Engl. J. Med. 349:1390-1391.
224. Szu SC, Taylor DN, Trofa AC, Clements JD, Shiloach J, Sadoff JC, Bryla DA, Robbins JB (1994) Laboratory and preliminary clinical characterization of Vi capsular polysaccharideprotein conjugate vaccines. Infect. Immun. 62:4440-4444.
225. Lin FY, Ho VA, Khiem HB, Trach DD, Bay PV, Thanh TC, Kossaczka Z, Bryla DA, Shiloach J, Robbins JB, Schneerson R, Szu SC (2001) The efficacy of a Salmonella typhi Vi conjugate vaccine in two-to-five-year-old children. N. Engl. J. Med. 344: 1263-1269.
226. Anon (2006) Evaluation of the safety, immunogenicity, and compatibility with DTP of an investigational Vi-rEPA(2) conjugate vaccine for typhoid fever when administered to infants in Vietnam concurrently with DTP. Available at: http://clinicaltrials.gov/ct2/show/nct00342628.
227. Kossaczka Z, Bystricky S, Bryla DA, Shiloach J, Robbins JB, Szu SC (1997) Synthesis and immunological properties of Vi and di-O-acetyl pectin protein conjugates with adipic acid dihydrazide as the linker. Infect. Immun. 65:2088-2093.
228. Anon (2006) Salmonella typhi Vi O-acetyl pectin-rEPA conjugate vaccine. Available at: http://clinicaltrials.gov/ct2/show/NCT00277147.
229. Scott DA, Komjathy SF, Hu BT, Baker S, Supan LA, Monahan CA, GruberW, Siber GR, Lockhart SP (2007) Phase 1 trial of a 13-valent pneumococcal conjugate vaccine in healthy adults. Vaccine 25:6164-6166.
230. Anon (2007) GlaxoSmithKline files meningococcal conjugate vaccine. Available at: http://www.gsk.com/media/pressreleases/2007/2007_03_30_GSK1006.htm.
231. Poolman J, Kaufhold A, De Grave D, Goldblatt D (2001) Clinical relevance of lower Hib response in DTPa-based combination vaccines. Vaccine 19:2280-2285.
232. Greenberg DP, Wong VK, Partridge S, Chang SJ, Jing J, Howe BJ, Ward JI (2000) Immunogenicity of a Haemophilus influenzae type b-tetanus toxoid conjugate vaccine when mixed with a diphtheria-tetanus-acellular pertussis-hepatitis B combination vaccine. Pediatr. Infect. Dis. J. 19:1135-1140.
233. O'Brien KL, Hochman M, Goldblatt D (2007) Combined schedules of pneumococcal conjugate and polysaccharide vaccines: Is hyporesponsiveness an issue? Lancet Infect. Dis. 7:597-606.
234. McVernon J, Mitchison NA, Moxon ER (2004) T helper cells and efficacy of Haemophilus influenzae type b conjugate vaccination. Lancet Infect. Dis. 4:40-43.
235. Ramsay ME, McVernon J, Andrews NJ, Heath PT, Slack MP (2003) Estimating Haemophilus influenzae type b vaccine effectiveness in England and Wales by use of the screening method. J. Infect. Dis. 188:481-485.
236. Maiden MC, Stuart JM (2002) Carriage of serogroup C meningococci 1 year after meningococcal C conjugate polysaccharide vaccination. Lancet 359:1829-1831.
237. Johnson NG, Ruggeberg JU, Balfour GF, Lee YC, Liddy H, Irving D, Sheldon J, Slack MP, Pollard AJ, Heath PT (2006) Haemophilus influenzae type b reemergence after combination immunization. Emerg. Infect. Dis. 12:937-941.
238. Auckland C, Gray S, Borrow R, Andrews N, Goldblatt D, Ramsay M, Miller E (2006) Clinical and immunologic risk factors for meningococcal C conjugate vaccine failure in the United Kingdom. J. Infect. Dis. 194:1745-1752.
239. Kelly DF, Pollard AJ, Moxon ER (2005) Immunological memory: The role of B cells in long-term protection against invasive bacterial pathogens. JAMA 294:3019-3023.
240. Diggle MA, Clarke SC (2005) Increased genetic diversity of Neisseria meningitidis isolates after the introduction of meningococcal serogroup C polysaccharide conjugate vaccines. J. Clin. Microbiol. 43:4649-4653.
241. Pichichero ME, Casey JR (2007) Emergence of a multiresistant serotype 19A pneumococcal strain not included in the 7-valent conjugate vaccine as an otopathogen in children. JAMA 298:1772-1778.
242. Hanage WP, Huang SS, Lipsitch M, Bishop CJ, Godoy D, Pelton SI, Goldstein R, Huot H, Finkelstein JA (2007) Diversity and antibiotic resistance among nonvaccine serotypes of Streptococcus pneumoniae carriage isolates in the post-heptavalent conjugate vaccine era. J. Infect. Dis. 195:347-352.
243. Singleton RJ, Hennessy TW, Bulkow LR, Hammitt LL, Zulz T, Hurlburt DA, Butler JC, Rudolph K, Parkinson A (2007) Invasive pneumococcal disease caused by nonvaccine serotypes among Alaska native children with high levels of 7-valent pneumococcal conjugate vaccine coverage. JAMA 297:1784-1792.
244. Beall B (2007) Vaccination with the pneumococcal 7-valent conjugate: A successful experiment but the species is adapting. Expert. Rev. Vaccines 6:297-300.
245. Trotter CL, Ramsay ME, Gray S, Fox A, Kaczmarski E (2006) No evidence for capsule replacement following mass immunisation with meningococcal serogroup C conjugate vaccines in England and Wales. Lancet Infect. Dis. 6:616-617.
246. Alcala B, Arreaza L, Salcedo C, Uria MJ, De La Fuente L, Vazquez JA (2002) Capsule switching among C : 2b : P1.2,5 meningococcal epidemic strains after mass immunization campaign, Spain. Emerg. Infect. Dis. 8:1512-1514.
247. Feikin DR, Levine O, Nelson C, Mohsnie E, Watt J, Wenger J, Kou U (2001) Estimating the local burden of Haemophilus influenzae type b (Hib) disease preventable by vaccination, a rapid assessment tool. Available at: www.who.int/vaccines-documents/DocsPDF01/www625.pdf.
248. Williams BG, Gouws E, Boschi-Pinto C, Bryce J, Dye C (2002) Estimates of world-wide distribution of child deaths from acute respiratory infections. Lancet Infect. Dis. 2:25-32.
249. Crisel RM, Baker RS, Dorman DE (1975) Capsular polymer of Haemophilus influenzae, type b. I. Structural characterization of the capsular polymer of strain Eagan. J. Biol. Chem. 250:4926-4930.
250. Bundle DR, Smith ICP, Jennings HJ (1974) Determination of the structure and conformation of bacterial polysaccharides by carbon 13 nuclear magnetic resonance. Studies on the group-specific antigens of Neisseria meningitidis serogroups A and X. J. Biol. Chem. 249:2275-2281.
251. Bhattacharjee AK, Jennings HJ, Kenny CP, Martin A, Smith IC (1975) Structural determination of the sialic acid polysaccharide antigens of Neisseria meningitidis serogroups B and C with carbon 13 nuclear magnetic resonance. J. Biol. Chem. 250:1926-1932.
252. Bhattacharjee AK, Jennings HJ, Kenny CP, Martin A, Smith IC (1976) Structural determination of the polysaccharide antigens of Neisseria meningitidis serogroups Y, W-135, and BO1. Can. J. Biochem. 54:1-8.
253. Heyns K, Kiessling G, LindenbergW, Paulsen H,Webster ME (1959) D-Galaktosaminuronsäure (2-Amino-2-desoxy-2-galakturonsäure) als baustein des Vi-Antigens. Chemische. Berichte. 92:2435-2438.
254. Lindberg B, Lindqvist B, Lonngren J, Powell DA (1980) Structural studies of the capsular polysaccharide from Streptococcus pneumoniae type 1. Carbohydr. Res. 78:111-117.
255. Jansson PE, Lindberg B, Anderson M, Lindquist U, Henrichsen J (1988) Structural studies of the capsular polysaccharide from Streptococcus pneumoniae type 2, a reinvestigation. Carbohydr. Res. 182:111-117.
256. Reeves RE, Goebel WF (1941) Chemoimmunological studies on the soluble specific substance of pneumococcus. V. The structure of the Type III polysaccharide. J. Biol. Chem. 139:511-519.
257. Jansson PE, Lindberg B, Lindquist U (1981) Structural studies of the capsular polysaccharide from Streptococcus pneumoniae type 4. Carbohydr. Res. 95:73-80.
258. Jansson PE, Lindberg B, Lindquist U (1985) Structural studies of the capsular polysaccharide from Streptococcus pneumoniae type 5. Carbohydr. Res. 140:101-110.
259. Kenne L, Lindberg B, Madden JK (1979) Structural studies of the capsular antigen from Streptococcus pneumoniae type 26. Carbohydr. Res. 73:175-182.
260. Moreau M, Richards JC, Perry MB, Kniskern PJ (1988) Application of high-resolution n.m.. spectroscopy to the elucidation of the structure of the specific capsular polysaccharide of Streptococcus pneumoniae type 7F. Carbohydr. Res. 182:79-99.
261. Jones JKN, Perry MB (1957) The structure of the Type VIII pneumococcus specific polysaccharide. J. Am. Chem. Soc. 79:2787-2793.
262. Jones C, Mulloy B, Wilson A, Dell A, Oates JE (1985) Structure of the capsular polysaccharide from Streptococcus pneumoniae type 9. J. Chem. Soc. Perkins Trans. 1: 1665-1673.
263. Perry MB, Daoust V, Carlo DJ (1981) The specific capsular polysaccharide of Streptococcus pneumoniae type 9V. Can. J. Biochem. 59:524-533.
264. Jones C (1995) Full assignment of the NMR spectrum of the capsular polysaccharide from Streptococcus pneumoniae serotype 10A. Carbohydr. Res. 269:175-181.
265. Richards JC, Perry MB, MoreauM(1988) Elucidation and comparison of the specific capsular polysaccharides of Streptococcus pneumoniae group 11 (11F, 11B, 11C, and 11A). Adv. Exp. Med. Biol. 228:595.
266. Leontein K, Lindberg B, Lonngren J (1981) Structural studies of the capsular polysaccharide from Streptococcus pneumoniae Type 12F. Can. J. Chem. 59:2081-2085.
267. Lindberg B, Lonngren J, Powell DA (1977) Structural studies on the specific type-14 pneumococcal polysaccharide. Carbohydr. Res. 58:177-186.
268. Jansson PE, Lindberg B, Lindquist U, Ljungberg J (1987) Structural studies of the capsular polysaccharide from Streptococcus pneumoniae types 15B and 15C. Carbohydr. Res. 162:111-116.
269. Jones C, Lemercinier X (2005) Full NMR assignment and revised structure for the capsular polysaccharide from Streptococcus pneumoniae type 15B. Carbohydr. Res. 340:403-409.
270. Jones C, Whitley C, Lemercinier X (2000) Full assignment of the proton and carbonNMR spectra and revised structure for the capsular polysaccharide from Streptococcus pneumoniae Type 17F. Carbohydr. Res. 325:192-201.
271. Lugowski C, Jennings HJ (1984) Structural determination of the capsular polysaccharide of Streptococcus pneumoniae type 18C (56). Carbohydr. Res. 131:119-129.
272. Katzenellenbogen E, Jennings HJ (1983) Structural determination of the capsular polysaccharide of Streptococcus pneumoniae type 19A (57). Carbohydr. Res. 124:235-245.
273. Jennings HJ, Rosell KG, Carlo DJ (1980) Structural determination of the capsular polysaccharide of Streptococcus pneumoniae type-19 (19F). Can. J. Chem. 58:1069-1074.
274. Richards JC, Perry MB, Carlo DJ (1983) The specific capsular polysaccharide of Streptococcus pneumoniae type 20. Biochem. Cell Biol. 61:178-190.
275. Richards JC, Perry MB, Kniskern PJ (1989) Structural analysis of the specific capsular polysaccharide of Streptococcus pneumoniae type 22F. Can. J. Chem. 67:1038-1050.
276. Richards JC, Perry MB (1988) Structure of the specific capsular polysaccharide of Streptococcus pneumoniae type 23F (American type 23). Biochem. Cell Biol. 66:758-771.
277. Lemercinier X, Jones C (2006) Full assignment of the 1H and 13C spectra and revision of the O-acetylation site of the capsular polysaccharide of Streptococcus pneumoniae Type 33F, a component of the current pneumococcal polysaccharide vaccine. Carbohydr. Res. 341:68-74.
278. Wuorimaa T, Kayhty H (2002) Current state of pneumococcal vaccines. Scand. J. Immunol. 56:111-129.
279. Schuerman L, Prymula R, Henckaerts I, Poolman J (2007) ELISA IgG concentrations and opsonophagocytic activity following pneumococcal protein D conjugate vaccination and relationship to efficacy against acute otitis media. Vaccine 25:1962-1968.
280. Kogan G, Brisson JR, Kasper DL, von Hunolstein C, Orefici G, Jennings HJ (1995) Structural elucidation of the novel type VII group B Streptococcus capsular polysaccharide by high resolution NMR spectroscopy. Carbohydr. Res. 277:1-9.
281. Kogan G, Uhrin D, Brisson JR, Paoletti LC, Blodgett AE, Kasper DL, Jennings HJ (1996) Structural and immunochemical characterization of the type VIII group B Streptococcus capsular polysaccharide. J. Biol. Chem. 271:8786-8790.